AVXS Abuzz, PTCT Slammed For Emflaza Deal, INNL Scouts For Buyer

Shares of AveXis Inc. were up more than 11% in extended trading on Thursday, following the completion of its phase I clinical study of AVXS-101, the first ever gene therapy studied for the treatment of spinal muscular atrophy Type 1.

from RTT - Biotech http://ift.tt/2n51OuD
via IFTTT